The GSK-3β inhibitors significantly decreased the relative number of BrdU-positive proliferating osteosarcoma and osteoblast cells (Figure 3A) and increased the relative number of TUNEL-positive cells undergoing apoptosis in the osteosarcoma cell lines, but not in hFOB1.19 osteoblast cells (Figure 3B). The gene discussed is GSK3B; the disease is osteosarcoma.